Rentschler Biopharma SE, a global CDMO for biopharmaceuticals, is donating 50,000 Euros to support the creation of the Albert Einstein Discovery Center. The discovery and activity center is intended to make the physicist’s legacy not only understandable but tangible to the public. It is located in Ulm, Einstein’s birthplace and today the scientific center of the region, and only a few kilometers away from Rentschler Biopharma’s headquarters in Laupheim.
 
“There are several aspects we share with Albert Einstein,” said Dr. Frank Mathias, CEO of Rentschler Biopharma, summarizing the reasons for the Company’s commitment. “As a leading biopharmaceutical company, the promotion of science is one of our core responsibilities. Innovation and groundbreaking research are not possible unless we provide curious and motivated people the opportunity to immerse themselves in the complex world of science. The construction of the Albert Einstein Discovery Center, therefore, is an excellent occasion to create educational opportunities in our region.”
 
Dr. Nancy Hecker-Denschlag, Chairwoman of the Albert Einstein Discovery Center Ulm e.V., is pleased that Rentschler Biopharma, a leading biopharmaceutical company from the region, has joined the group of lead sponsors, called ‘The First 11’. “Rentschler Biopharma is a perfect fit with the future Albert Einstein Discovery Center Ulm because its focus is not only on providing scientific knowledge, but also on offering activities in the ‘hands-on science center’ we are planning. This is intended to create enthusiasm, especially among young people, for learning about math and science.”